Difference in the in vitro uptake of bromodeoxyuridine between liver cirrhosis with and without hepatocellular carcinoma.
With the aim of examining increasing deoxyribonucleic acid (DNA) synthesis of liver cirrhotic tissue when hepatocellular carcinoma (HCC) is developing, bromodeoxyuridine labeling indices (BrdU LI) of liver biopsy specimens from 19 control cirrhotic (control LC) patients without HCC, 19 cirrhotic patients with HCC, and from six control subjects were examined using an in vitro labeling technique. The mean BrdU LI +/- SD of HCC cancerous portion, HCC non-cancerous cirrhotic portion, control LC, and of control subjects were 7.2 +/- 2.9%, 3.3 +/- 1.5%, 2.1 +/- 1.7%, and 0.25 +/- 0.09%, respectively. Interesting enough, there was a significant difference (P less than 0.05) between the non-cancerous cirrhotic portion and control LC. Although all 17 non-cancerous cirrhotic portion belonged to the high LI group (greater than or equal to 1.5%), 10 of 19 in the control LC belonged to the low LI group (less than 1.5%) (P less than 0.001). The authors conclude that HCC would develop in the cirrhotics with high DNA synthetic potency.
Tarao
K
K
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Shimizu
A
A
Harada
M
M
Kuni
Y
Y
Ito
Y
Y
Tamai
S
S
Iimori
K
K
Sugimasa
Y
Y
Takemiya
S
S
Okamoto
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001973:Bromodeoxyuridine; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000235:genetics / Q000378:metabolism*; D004261:DNA Replication; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008103:Liver Cirrhosis / Q000150:complications / Q000378:metabolism*; D008113:Liver Neoplasms / Q000150:complications / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine